TCMD
VENTE TOTALE: 10 978 titres (~323 242,82 $ US)
- Insiders
- Dodd Sheri Louise
- Total bought
- —
- Total sold
- $323,243
- Last activity
- 2026-08-10
- Last synced
-
2026-08-16 09:56:14
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-13
TCMD exhibits a genuinely strong financial foundation — high liquidity (90), improving fundamentals (85), and a credible deleveraging trajectory — which anchors the investment thesis.
The first sentence of the analysis written for TCMD on 2026-08-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 75.2% | 74.0% | 71.1% | 71.3% | 71.2% | |
| Ebit Margin | 9.8% | 8.7% | 7.3% | -5.1% | -1.1% | |
| Ebitda Margin | 11.8% | 11.0% | 9.6% | 0.7% | 0.7% | |
| Operating Profit Margin | 8.9% | 7.6% | 6.6% | -5.2% | -0.8% | |
| Pretax Profit Margin | 9.5% | 8.0% | 5.7% | -6.3% | -1.1% | |
| Continuous Operations Profit Margin | 5.8% | 5.8% | 10.4% | -7.2% | -5.7% | |
| Net Profit Margin | 5.8% | 5.8% | 10.4% | -7.2% | -5.7% | |
| Bottom Line Profit Margin | 5.8% | 5.8% | 10.4% | -7.2% | -5.7% | |
| Current Ratio | 4.033 | 4.362 | 3.539 | 1.862 | 3.295 | |
| Quick Ratio | 3.690 | 3.904 | 2.990 | 1.502 | 2.737 | |
| Solvency Ratio | 0.467 | 0.292 | 0.399 | -0.026 | -0.070 | |
| Cash Ratio | 2.037 | 2.318 | 1.487 | 0.341 | 0.819 | |
| Price To Earnings Ratio | 34.940 | 24.127 | 11.532 | -12.899 | -31.717 | |
| Price To Earnings Growth Ratio | 2.067 | -0.564 | -0.048 | -0.267 | -0.017 | |
| Forward Price To Earnings Growth Ratio | 2.067 | -0.564 | -0.048 | -0.267 | -0.017 | |
| Price To Earnings Diluted Ratio | 35.366 | 24.471 | 11.626 | -12.899 | -31.717 | |
| Price To Earnings Diluted Growth Ratio | 2.063 | -0.568 | -0.049 | -0.267 | -0.017 | |
| Price To Book Ratio | 3.030 | 1.889 | 1.693 | 1.898 | 2.927 | |
| Price To Sales Ratio | 2.013 | 1.396 | 1.195 | 0.934 | 1.804 | |
| Price To Free Cash Flow Ratio | 16.406 | 10.725 | 9.823 | 70.046 | 1,359.644 | |
| Price To Operating Cash Flow Ratio | 15.494 | 10.063 | 9.143 | 44.227 | 142.631 | |
| Debt To Assets Ratio | 0.058 | 0.151 | 0.179 | 0.283 | 0.330 | |
| Debt To Equity Ratio | 0.073 | 0.208 | 0.260 | 0.595 | 0.629 | |
| Debt To Capital Ratio | 0.068 | 0.172 | 0.206 | 0.373 | 0.386 | |
| Long Term Debt To Capital Ratio | 0.055 | 0.097 | 0.119 | 0.274 | 0.288 | |
| Financial Leverage Ratio | 1.251 | 1.375 | 1.453 | 2.100 | 1.905 | |
| Working Capital Turnover Ratio | 2.524 | 2.430 | 3.437 | 3.669 | 2.364 | |
| Operating Cash Flow Ratio | 1.045 | 0.999 | 0.873 | 0.081 | 0.076 | |
| Operating Cash Flow Sales Ratio | 0.130 | 0.139 | 0.131 | 0.021 | 0.013 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | 0.938 | 0.931 | 0.631 | 0.105 | |
| Debt Service Coverage Ratio | 25.787 | 5.127 | 5.513 | -0.112 | -2.747 | |
| Interest Coverage Ratio | 28.207 | 10.638 | 4.350 | -4.576 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 13.753 | 12.130 | 1.755 | 0.889 | |
| Operating Cash Flow Coverage Ratio | 2.683 | 0.901 | 0.712 | 0.072 | 0.033 | |
| Capital Expenditure Coverage Ratio | 17.988 | 16.204 | 14.452 | 2.713 | 1.117 | |
| Dividend Paid And Capex Coverage Ratio | 17.988 | 16.204 | 14.452 | 2.713 | 1.117 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 15.270 | 11.116 | 12.007 | 160.664 | 308.100 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 75.2% | ▲1.2% | ▲2.6% |
| Ebit Margin | 9.8% | ▲1.1% | ▲5.9% |
| Ebitda Margin | 11.8% | ▲0.8% | ▲5.1% |
| Operating Profit Margin | 8.9% | ▲1.3% | ▲5.5% |
| Pretax Profit Margin | 9.5% | ▲1.5% | ▲6.3% |
| Continuous Operations Profit Margin | 5.8% | 0.0% | ▲4.0% |
| Net Profit Margin | 5.8% | 0.0% | ▲4.0% |
| Bottom Line Profit Margin | 5.8% | 0.0% | ▲4.0% |
| Current Ratio | 4.033 | ▼-0.330 | ▲0.615 |
| Quick Ratio | 3.690 | ▼-0.213 | ▲0.726 |
| Solvency Ratio | 0.468 | ▲0.175 | ▲0.255 |
| Cash Ratio | 2.037 | ▼-0.281 | ▲0.637 |
| Price To Earnings Ratio | 34.940 | ▲10.813 | ▲29.743 |
| Price To Earnings Growth Ratio | 2.067 | ▲2.632 | ▲1.833 |
| Forward Price To Earnings Growth Ratio | 2.067 | ▲2.632 | ▲1.833 |
| Price To Earnings Diluted Ratio | 35.366 | ▲10.894 | ▲29.996 |
| Price To Earnings Diluted Growth Ratio | 2.063 | ▲2.631 | ▲1.831 |
| Price To Book Ratio | 3.030 | ▲1.141 | ▲0.743 |
| Price To Sales Ratio | 2.013 | ▲0.617 | ▲0.545 |
| Price To Free Cash Flow Ratio | 16.406 | ▲5.681 | ▼-276.923 |
| Price To Operating Cash Flow Ratio | 15.494 | ▲5.431 | ▼-28.818 |
| Debt To Assets Ratio | 0.058 | ▼-0.093 | ▼-0.142 |
| Debt To Equity Ratio | 0.073 | ▼-0.135 | ▼-0.280 |
| Debt To Capital Ratio | 0.068 | ▼-0.104 | ▼-0.173 |
| Long Term Debt To Capital Ratio | 0.055 | ▼-0.042 | ▼-0.112 |
| Financial Leverage Ratio | 1.251 | ▼-0.124 | ▼-0.366 |
| Working Capital Turnover Ratio | 2.524 | ▲0.094 | ▼-0.361 |
| Operating Cash Flow Ratio | 1.045 | ▲0.046 | ▲0.430 |
| Operating Cash Flow Sales Ratio | 0.130 | ▼-0.009 | ▲0.043 |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | ▲0.006 | ▲0.234 |
| Debt Service Coverage Ratio | 25.787 | ▲20.660 | ▲19.073 |
| Interest Coverage Ratio | 28.207 | ▲17.569 | ▲20.483 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-13.753 | ▼-5.705 |
| Operating Cash Flow Coverage Ratio | 2.683 | ▲1.782 | ▲1.803 |
| Capital Expenditure Coverage Ratio | 17.988 | ▲1.784 | ▲7.493 |
| Dividend Paid And Capex Coverage Ratio | 17.988 | ▲1.784 | ▲7.493 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 15.270 | ▲4.154 | ▼-86.162 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $663.3M | $409.1M | $327.8M | $230.4M | $375.3M | |
| Enterprise value | $595.8M | $359.9M | $317.2M | $280.7M | $427.6M | |
| EV / Sales | 1.81x | 1.23x | 1.16x | 1.14x | 2.06x | |
| EV / Op. cash flow | 13.92x | 8.85x | 8.85x | 53.88x | 162.54x | |
| EV / Free cash flow | 14.74x | 9.43x | 9.50x | 85.34x | 1549.43x | |
| EV / EBITDA | 15.27x | 11.12x | 12.01x | 160.66x | 308.10x | |
| Net debt / EBITDA | -1.73x | -1.52x | -0.40x | 28.79x | 37.74x | |
| Current ratio | 4.03x | 4.36x | 3.54x | 1.86x | 3.29x | |
| Income quality | 2.24x | 2.40x | 1.26x | -0.29x | -0.22x | |
| Graham number | $13 | $12 | $15 | — | — | |
| Graham net-net | $3 | $3 | $1 | -$2 | -$1 | |
| Tax burden | 60.9% | 72.2% | 180.8% | 115.5% | 515.1% | |
| Interest burden | 96.8% | 91.8% | 79.2% | 122.0% | 100.0% | |
| Working capital | $124.2M | $136.9M | $104.2M | $55.4M | $79.1M | |
| Invested capital | $213.4M | $232.9M | $207.3M | $164.3M | $195.0M | |
| Return on assets | 7.0% | 5.7% | 10.1% | -7.0% | -4.8% | |
| Operating ROA | 10.2% | 7.7% | 6.7% | -5.1% | -0.8% | |
| Return on tangible assets | 9.4% | 7.6% | 14.0% | -10.3% | -7.4% | |
| Return on equity | 8.7% | 7.8% | 14.7% | -14.7% | -9.2% | |
| Return on invested capital | 7.5% | 6.1% | 7.3% | -6.5% | -0.8% | |
| Return on capital employed | 12.6% | 8.6% | 7.5% | -6.7% | -0.8% | |
| Earnings yield | 2.9% | 4.1% | 8.7% | -7.8% | -3.1% | |
| Free cash flow yield | 6.1% | 9.3% | 10.2% | 1.4% | 0.1% | |
| Capex / Op. cash flow | 5.6% | 6.2% | 6.9% | 36.9% | 89.5% | |
| Capex / Depreciation | 35.8% | 36.9% | 38.2% | 30.6% | 63.6% | |
| Capex / Sales | 0.7% | 0.9% | 0.9% | 0.8% | 1.1% | |
| SG&A / Sales | 63.7% | 62.5% | 61.7% | 67.8% | 69.0% | |
| R&D / Sales | 2.6% | 3.0% | 2.9% | 2.9% | 2.7% | |
| Stock comp / Sales | 2.5% | 2.7% | 2.8% | 3.9% | 4.9% | |
| Intangibles / Total assets | 25.6% | 24.8% | 27.6% | 31.9% | 34.9% | |
| Days sales outstanding | 49d | 56d | 57d | 81d | 87d | |
| Days payables outstanding | 22d | 27d | 31d | 51d | 31d | |
| Operating cycle | 111d | 145d | 161d | 200d | 204d | |
| Cash conversion cycle | 89d | 118d | 130d | 149d | 173d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+62.1%EV / Sales ▲+47.2%EV / EBITDA ▲+37.4%EV / Op. cash flow ▲+5.066Earnings yield ▼-0.013Graham number ▲+1.367
Profitability
Return on equity ▲+0.009Return on assets ▲+0.013Return on invested capital ▲+0.015Return on capital employed ▲+0.039Operating ROA ▲+0.026Income quality ▼-0.154Tax burden ▼-0.113
Efficiency
Days sales outstanding ▼-7.383Days payables outstanding ▼-4.858Operating cycle ▼-34.115Cash conversion cycle ▼-29.257Capex / Sales ▼-0.001R&D / Sales ▼-0.004
Balance-sheet strength
Current ratio ▼-0.330Net debt / EBITDA ▼-0.208Working capital ▼-12649000.000Invested capital ▼-19592000.000Intangibles / Total assets ▲+0.008
Change over 5 years
Valuation
Market cap ▲+76.8%EV / Sales ▼-12.0%EV / EBITDA ▼-95.0%EV / Op. cash flow ▼-148.622Earnings yield ▲+0.060
Profitability
Return on equity ▲+0.179Return on assets ▲+0.118Return on invested capital ▲+0.084Return on capital employed ▲+0.134Operating ROA ▲+0.111Income quality ▲+2.466Tax burden ▼-4.542
Efficiency
Days sales outstanding ▼-38.201Days payables outstanding ▼-8.474Operating cycle ▼-92.843Cash conversion cycle ▼-84.369Capex / Sales ▼-0.004R&D / Sales ▼-0.001
Balance-sheet strength
Current ratio ▲+0.738Net debt / EBITDA ▼-39.468Working capital ▲+45124000.000Invested capital ▲+18391000.000Intangibles / Total assets ▼-0.092
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2019-01-23 | Donna Shalala | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-10 Tactile Systems Technology, Inc. (TCMD) Q2 2026 Earnings Call Transcript Tactile Systems Technology, Inc. (TCMD) Q2 2026 Earnings Call Transcript
- 2026-08-10 Tactile Systems Technology Q2 Earnings Call Highlights Tactile Systems Technology NASDAQ: TCMD, doing business as Tactile Medical, reported second-quarter revenue growth and higher profitability, led by its lymphedema business, while updating its full-year outlook to reflect temporary inventory effects in its airway-clearance segment.
- 2026-08-10 Tactile Systems Technology (TCMD) Beats Q2 Earnings and Revenue Estimates Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.14 per share a year ago.
- 2026-07-21 Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026 MINNEAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2026 financial results will be released after the market closes on Monday, August 10, 2026.
- 2026-07-13 Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression
- 2026-06-29 Tactile Systems Technology (TCMD) Moves 8.1% Higher: Will This Strength Last? Tactile Systems Technology (TCMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-06-02 Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system. The next-generation system maintains its indication for use as a treatment option for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations, while introducing enhancements to patient comfort, ease of use, and connected care capabilities to support long-term therapy adherence.
- 2026-05-20 Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the William Blair 46th Annual Growth Stock Conference, which is being held at the Loews Hotel in Chicago, IL, from June 2-4, 2026. Management will present on Tuesday, June 2, at 9:20 a.m. Central Time.